Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.

"We can green up that valley of death," Viehbacher said in an interview with Scrip. Boston Pharmaceuticals was established with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip